Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate vs oral atypical antipsychotics.
CONCLUSIONS: Treatment with PP1M versus OAAs may reduce AP polypharmacy and increase AP persistence in comorbid patients with schizophrenia, without increasing total healthcare costs. Comorbidities are a highly prevalent driver of excess mortality in this vulnerable population; thus future studies should specifically address real-world effectiveness of therapies (including LAIs) for these patients.
PMID: 29452492 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Eating Disorders & Weight Management | Endocrinology | Healthcare Costs | Heart | Hypertension | Invega | Invega Sustenna | Medicaid | Obesity | Research | Schizophrenia | Study